In a comprehensive analysis of blood gene expression profiles from canakinumab-treated sJIA patients [13, 43], the activity of the IL-1 signaling pathway itself was not suppressed in correlation with the treatment response. The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.